Skip to main content
ONCBeOne Medicines Ltd.Buy Wait6.6·$350.93+1.28%

BeOne Medicines (ONC) Q2 2026 earnings — TrendMatrix coverage

BEAT+25.7% vs estimateEPS $2.05 vs $1.63 estCurrent verdict Buy (Wait) 6.6/10

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure

Event detail · Q2 2026

Key numbers

Reported EPS
$2.05
Estimate
$1.63
Surprise
+25.7%
Revenue (period 2026-06-30)
$1.71B
Score today
6.6/10

Revenue source: xbrl.

Report record · Q2 2026

How the report landed

BeOne Medicines (ONC) beat the $1.63 estimate with diluted EPS of $2.05 — a large 25.7% upside surprise.

Current read · as of 2026-09-17

Where TrendMatrix's rating stands now

TrendMatrix currently rates ONC Buy (Wait) at 6.6/10; no pre/post engine snapshot brackets this report.

3 of the last 4 quarters beat the estimate; this quarter's +25.7% surprise compares with a +35.1% four-quarter average. Next scheduled report: 2026-11-05.

What supports the rating

  • V7 quality resilience bonus: +0.2 (Q=7.7 in RISK_OFF)
  • Sector modifier (Healthcare): +0.5

What argues against it

  • Concentration risk — Product: BRUKINSA
  • RISK-OFF: MID-cap BUY_NOW needs quality>=8.5 or MoS>=50%

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current engine read

The levels TrendMatrix's engine tracks

Current price
$350.93
Entry target
$341.44
Price target
$389.52
Stop
$323.55
Upside to target
+11.0%
Reward-to-risk
2.3:1

The stock trades at 63.3× trailing but 33.6× forward earnings — consensus estimates already build in a substantial earnings recovery.

Risk check: RSI 28 — a level conventionally read as oversold.

Model outputs from TrendMatrix’s engine as of 2026-09-17 — shown for context, not personalized investment advice.

Healthcare context

ONC at TrendMatrix's latest read

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry
Biotechnology
Market cap
$39.20B
P/E (fwd)
33.6
P/E (ttm)
63.3
52-week range
$253.95$385.22
Off 52-week high
8.9%
RSI (14)
28
Volume vs avg
1.03×
Score today
6.6/10

Earnings figures are sourced from TrendMatrix’s pipeline (EPS: existing earnings extraction; revenue: SEC XBRL company facts where available, yfinance-provisional otherwise). Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home Stocks ONC Earnings Q2 2026 earnings